Arlington Research Center

Running trials

• Recruiting

  A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

  NCT07783425· Phase 3· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

  NCT06863961· Phase 2· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

  NCT06973291· Phase 3· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

  NCT06108544· Phase 3· Source

• Terminated

  The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

  NCT05696392· Phase 4· Source

• Terminated

  A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

  NCT05732454· Phase 2/3· Source

• Completed

  Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

  NCT05456529· Phase 3· Source

• Completed

  A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

  NCT04921969· Phase 3· Source